Benzinga | Jan 15, 2021 07:57AM EST

B of A Securities Downgrades Esperion Therapeutics to Neutral, Announces $35 Price Target

B of A Securities analyst Geoff Meacham downgrades Esperion Therapeutics (NASDAQ:ESPR) from Buy to Neutral and announces $35 price target.